Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Work In Process (2020 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Work In Process for 6 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Work In Process fell 15.87% year-over-year to $3.0 million, compared with a TTM value of $3.0 million through Dec 2025, down 15.87%, and an annual FY2025 reading of $3.0 million, down 15.87% over the prior year.
  • Work In Process was $3.0 million for Q4 2025 at Karyopharm Therapeutics, up from $2.9 million in the prior quarter.
  • Across five years, Work In Process topped out at $4.2 million in Q2 2025 and bottomed at $781000.0 in Q1 2021.
  • Average Work In Process over 5 years is $2.3 million, with a median of $1.9 million recorded in 2021.
  • The sharpest move saw Work In Process surged 193.34% in 2021, then plummeted 40.68% in 2023.
  • Year by year, Work In Process stood at $1.9 million in 2021, then dropped by 0.9% to $1.9 million in 2022, then decreased by 7.77% to $1.7 million in 2023, then soared by 104.5% to $3.5 million in 2024, then dropped by 15.87% to $3.0 million in 2025.
  • Business Quant data shows Work In Process for KPTI at $3.0 million in Q4 2025, $2.9 million in Q3 2025, and $4.2 million in Q2 2025.